Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cfintracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.
|Number of pages||3|
|State||Published - May 18 1985|
Bibliographical noteFunding Information:
We thank the US Department of Energy for the 252 caused in this study and the American Cancer Society for financial support of the ongoing randomised clinical trial. We thank Mrs Angela Sandifer for expert assistance. Correspondence should be addressed to Y. M., Department of Radiation Medicine, Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084, USA.
ASJC Scopus subject areas
- Medicine (all)